Top

Archives of Osteoporosis

Published in:

Open Access 01-12-2023 | Osteoporosis | Original Article

The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial

Authors: Teruki Sone, Kazuhiro Ohnaru, Takumi Sugai, Akiko Yamashita, Nobukazu Okimoto, Tetsuo Inoue, Toshio Matsumoto

Published in: Archives of Osteoporosis | Issue 1/2023

Abstract

Summary

Daily subcutaneous injection of 80 μg abaloparatide increased bone mineral density in Japanese patients with osteoporosis at high fracture risk in the ACTIVE-J trial. Dual-energy X-ray absorptiometry–based hip structural analysis from ACTIVE-J data showed improved hip geometry and biomechanical properties with abaloparatide compared with placebo.

Purpose

Abaloparatide (ABL) increased bone mineral density (BMD) in Japanese patients with osteoporosis at high fracture risk in the ACTIVE-J trial. To evaluate the effect of ABL on hip geometry and biomechanical properties, hip structural analysis (HSA) was performed using ACTIVE-J trial data.

Methods

Hip dual-energy X-ray absorptiometry scans from postmenopausal women and men (ABL, n = 128; placebo, n = 65) at baseline and up to week 78 were analyzed to extract bone geometric parameters at the narrow neck (NN), intertrochanteric region (IT), and proximal femoral shaft (FS). Computed tomography (CT)-based BMD and HSA indices were compared between baseline and week 78.

Results

ABL treatment showed increased mean percent change from baseline to week 78 in cortical thickness at the NN (5.3%), IT (5.3%), and FS (2.9%); cross-sectional area at the NN (5.0%), IT (5.0%), and FS (2.6%); cross-sectional moment of inertia at the NN (7.6%), IT (5.1%), and FS (2.5%); section modulus at the NN (7.4%), IT (5.4%), and FS (2.4%); and decreased mean percent change in buckling ratio (BR) at the IT (− 5.0%). ABL treatment showed increased mean percent change in total volumetric BMD (vBMD; 2.7%) and trabecular vBMD (3.2%) at the total hip and decreased mean percent change in BR at femoral neck (− 4.1%) at week 78 vs baseline. All the changes noted here were significant vs placebo (P < 0.050 using t-test).

Conclusion

A 78-week treatment with ABL showed improvement in HSA parameters associated with hip geometry and biomechanical properties vs placebo.

Trial registration

JAPIC CTI-173575

Available only for authorised users

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795. https://doi.org/10.1001/jama.285.6.785CrossRef

Föger-Samwald U, Dovjak P, Azizi-Semrad U, Kerschan-Schindl K, Pietschmann P (2020) Osteoporosis: pathophysiology and therapeutic options. EXCLI J 19:1017–1037. https://doi.org/10.17179/excli2020-2591CrossRefPubMedPubMedCentral

Dempster DW (2011) Osteoporosis and the burden of osteoporosis-related fractures. Am J Manag Care 17(Suppl 6):S164–S169PubMed

Takusari E, Sakata K, Hashimoto T, Fukushima Y, Nakamura T, Orimo H (2020) Trends in hip fracture incidence in Japan: estimates based on nationwide hip fracture surveys from 1992 to 2017. JBMR Plus 5:e10428. https://doi.org/10.1002/jbm4.10428CrossRefPubMedPubMedCentral

D’Ambrogio E (2020) Japan’s ageing society. European Parliamentary Research Service. https://www.europarl.europa.eu/RegData/etudes/BRIE/2020/659419/EPRS_BRI(2020)659419_EN.pdf. Accessed 24 Jul 2023

Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Arch Osteoporos 7:3–20. https://doi.org/10.1007/s11657-012-0109-9CrossRefPubMedPubMedCentral

Sone T, Kon N, Gaither KW, Okubo N, Osakabe T, Nakayama Y, Fukunaga M, Ito M, Nakamura T (2017) Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis. Bone Rep 7:164–171. https://doi.org/10.1016/j.bonr.2017.11.002CrossRefPubMedPubMedCentral

Miyauchi A, Dinavahi RV, Crittenden DB, Yang W et al (2019) Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos 14:59. https://doi.org/10.1007/s11657-019-0608-zCrossRefPubMedPubMedCentral

Nakamura T, Sugimoto T, Nakano T et al (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106. https://doi.org/10.1210/jc.2011-3479CrossRefPubMed

10.

Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441. https://doi.org/10.1056/NEJM200105103441904CrossRefPubMed

11.

Bodenner D, Redman C, Riggs A (2007) Teriparatide in the management of osteoporosis. Clin Interv Aging 2:499–507. https://doi.org/10.2147/cia.s241CrossRefPubMedPubMedCentral

12.

Tsai JN, Uihlein AV, Burnett-Bowie SM, Neer RM, Derrico NP, Lee H, Bouxsein ML, Leder BZ (2016) Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J Clin Endocrinol Metab 101:2023–2030. https://doi.org/10.1210/jc.2016-1160CrossRefPubMedPubMedCentral

13.

Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J Clin Endocrinol Metab 99:1694–1700. https://doi.org/10.1210/jc.2013-4440CrossRefPubMedPubMedCentral

14.

Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722–733. https://doi.org/10.1001/jama.2016.11136CrossRefPubMed

15.

Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949–2957. https://doi.org/10.1210/jc.2018-00163CrossRefPubMedPubMedCentral

16.

Matsumoto T, Soen S, Tanaka S, Yamashita A, Inoue T (2022) Abaloparatide increases lumbar spine and hip BMD in Japanese patients with osteoporosis: the phase 3 ACTIVE-J study. J Clin Endocrinol Metab 107:e4222–e4231. https://doi.org/10.1210/clinem/dgac486CrossRefPubMedPubMedCentral

17.

Link TM (2012) Osteoporosis imaging: state of the art and advanced imaging. Radiology 263:3–17. https://doi.org/10.1148/radiol.12110462CrossRefPubMedPubMedCentral

18.

Takada J, Katahira G, Iba K, Yoshizaki T, Yamashita T (2011) Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis. J Bone Miner Metab 29:458–465. https://doi.org/10.1007/s00774-010-0242-8CrossRefPubMed

19.

Kaptoge S, Beck TJ, Reeve J, Stone KL, Hillier TA, Cauley JA, Cummings SR (2008) Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res 23:1892–1904. https://doi.org/10.1359/jbmr.080802CrossRefPubMedPubMedCentral

20.

Winzenrieth R, Humbert L, Boxberger JI, Weiss RJ, Wang Y, Kostenuik P (2021) Abaloparatide effects on cortical volumetric BMD and estimated strength indices of hip subregions by 3D-DXA in women with postmenopausal osteoporosis. J Clin Densitom 25:392–400. https://doi.org/10.1016/j.jocd.2021.11.007CrossRefPubMed

21.

Winzenrieth R, Kostenuik P, Boxberger J, Wang Y, Humbert L (2022) Proximal femur responses to sequential therapy with abaloparatide followed by alendronate in postmenopausal women with osteoporosis by 3D modeling of hip dual-energy X-ray absorptiometry (DXA). JBMR Plus 6:e10612. https://doi.org/10.1002/jbm4.10612CrossRefPubMedPubMedCentral

22.

Nakamura T, Turner CH, Yoshikawa T et al (1994) Do variations in hip geometry explain differences in hip fracture risk between Japanese and white Americans? J Bone Miner Res 9:1071–1076. https://doi.org/10.1002/jbmr.5650090715CrossRefPubMed

23.

Beck TJ (2002) Hip Structural Analysis (HSA) Program (BMD and structural geometry methodology) as used to create NHANES III dataset. https://wwwn.cdc.gov/nchs/data/nhanes3/17a/hip_methods.pdf. Accessed 24 Jul 2023

24.

Beck TJ, Broy SB (2015) Measurement of hip geometry-technical background. J Clin Densitom 18:331–337. https://doi.org/10.1016/j.jocd.2015.06.006CrossRefPubMed

25.

Ohnaru K, Sone T, Tanaka K, Akagi K, Ju YI, Choi HJ, Tomomitsu T, Fukunaga M (2013) Hip structural analysis: a comparison of DXA with CT in postmenopausal Japanese women. SpringerPlus 2:331. https://doi.org/10.1186/2193-1801-2-331CrossRefPubMedPubMedCentral

26.

Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gluer CC (2010) Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 25:472–481. https://doi.org/10.1359/jbmr.090820CrossRefPubMed

27.

Dempster DW, Zhou H, Rao SD (2021) Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis. J Bone Miner Res 36:644–653. https://doi.org/10.1002/jbmr.4243CrossRefPubMed

28.

Prevrhal S, Fox JC, Shepherd JA, Genant HK (2003) Accuracy of CT-based thickness measurement of thin structures: modeling of limited spatial resolution in all three dimensions. Med Phys 30:1–8. https://doi.org/10.1118/1.1521940CrossRefPubMed

29.

Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005) Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948–958. https://doi.org/10.1016/j.bone.2005.03.003CrossRefPubMed

30.

Sone T, Ito M, Fukunaga M, Tomomitsu T, Sugimoto T, Shiraki M, Yoshimura T, Nakamura T (2014) The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk. Bone 64:75–81. https://doi.org/10.1016/j.bone.2014.04.004CrossRefPubMed

31.

Mochizuki T, Yano K, Ikari K, Kawakami K, Hiroshima R, Koenuma N, Ishibashi M, Shirahata T (2016) Hip structure analysis by DXA of teriparatide treatment: a 24-month follow-up clinical study. J Orthop 13:414–418. https://doi.org/10.1016/j.jor.2016.09.001CrossRefPubMedPubMedCentral

Title: The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial
Authors: Teruki Sone
Kazuhiro Ohnaru
Takumi Sugai
Akiko Yamashita
Nobukazu Okimoto
Tetsuo Inoue
Toshio Matsumoto
Publication date: 01-12-2023
Publisher: Springer London
Keywords: Osteoporosis
Osteoporosis
Published in: Archives of Osteoporosis / Issue 1/2023
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-023-01344-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial

Abstract

Summary

Purpose

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2023

Prevalence of and risk factors for vertebral fracture and low bone mineral density among Peruvian women aging with HIV

Correction to: Hip fracture incidence and post-fracture mortality in Victoria, Australia: a state-wide cohort study

Bone mineral density response to antiosteoporotic drugs in older depressed adults

Association between traffic-related air pollution and osteoporotic fracture hospitalizations in inland and coastal areas: evidences from the central areas of two cities in Shandong Province, China

Hip fracture incidence and post-fracture mortality in Victoria, Australia: a state-wide cohort study

The total number of patients with any of four major fragility fractures decreased during the first wave of the COVID-19 epidemic in Japan, commencing before the state of emergency declaration, which was not as enforceable as lockdown